The Breast
Volume 19, Issue 3 , Pages 214-218 , June 2010

Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies

  • Vito Lorusso

      Affiliations

    • Medical Oncology Unit, Vito Fazzi Hospital, Lecce 73100, Italy
    • Corresponding Author InformationCorresponding author. Medical Oncology Dept., Vito Fazzi Hospital, Lecce 73100, Italy. Tel.: +39 8 3266 1981; fax: +39 8 3266 1962.
    • ,
  • Saverio Cinieri

      Affiliations

    • Medical Oncology Unit, Hospital Perrino, Brindisi, Italy
    • Medical Oncology Unit, European Institute of Oncology, Milan, Italy
    • ,
  • Marianna Giampaglia

      Affiliations

    • Medical Oncology Unit, Vito Fazzi Hospital, Lecce 73100, Italy
    • ,
  • Mariangela Ciccarese

      Affiliations

    • Medical Oncology Unit, Vito Fazzi Hospital, Lecce 73100, Italy
    • ,
  • Andrea Tinelli

      Affiliations

    • Medical Oncology Unit, Vito Fazzi Hospital, Lecce 73100, Italy
    • ,
  • Vincenzo Chiuri

      Affiliations

    • Medical Oncology Unit, Vito Fazzi Hospital, Lecce 73100, Italy
    • ,
  • Corrado Manca

      Affiliations

    • Medical Oncology Unit, Vito Fazzi Hospital, Lecce 73100, Italy
    • ,
  • Nicola Silvestris

      Affiliations

    • Medical and Experimental Oncology Unit, Oncology Institute, Bari, Italy
    • ,
  • Giampiero Gasparini

      Affiliations

    • Medical Oncology Unit, S. Filippo Neri Hospital, Roma, Italy
    • ,
  • Giuseppe Colucci

      Affiliations

    • Medical and Experimental Oncology Unit, Oncology Institute, Bari, Italy

Received 8 June 2009 ,Revised 20 January 2010 ,Accepted 20 January 2010.

References 

  1. De Vita VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. Philadelphia: J.B. Lippincott Co.; 1993;pp. 1264–1332
  2. Tripathy D. Systemic therapy for advanced breast cancer. Breast J. 2004;10(Suppl. 1):26–27
  3. Sledge GW, Antman KH. Progress in chemotherapy for metastatic breast cancer. Sem Oncol. 1992;19:317–332
  4. Ahmann DL, Schaid DJ, Bisel HF, Hahn RG, Edmonson JH, Ingle JN, et al. The effect on survival of initial chemotherapy in advanced breast cancer. Polychemotherapy versus single drug. J Clin Oncol. 1987;5:1928–1932
  5. Jassem J, Pieńkowski T, Płuzańska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001;19:1707–1715
  6. Nabholtz JM, Reese DM, Lindsay MA, Riva A. Docetaxel in the treatment of breast cancer: an update on recent studies. Semin Oncol. 2002;29(3 Suppl. 12):28–34
  7. Crown J, Diéras V, Kaufmann M, von Minckwitz G, Kaye S, Leonard R, et al. Chemotherapy for metastatic breast cancer – report of an European expert panel. Lancet Oncol. 2002;3:719–727
  8. Monfardini S, Beda M, Fratino L. Breast cancer: single agents chemotherapy. Tumori. 2002;88(1 Suppl. 1):S55–S56
  9. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, et al. Preliminary studies of a novel oral fluoropyrimidinecarbamate: capecitabine. J Clin Oncol. 1998;16:1795–1802
  10. Mackean M, Planting A, Twelves C, et al. A phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998;16:2977–2985
  11. Schilsky RL. Pharmacology and clinical status of capecitabine. Oncology (Williston Park). 2000;14:1297–1306
  12. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol. 2001;12:1247–1254
  13. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II trial of Xeloda (capecitabine) in paclitaxel – refractory metastatic breast cancer (MBC). J Clin Oncol. 1999;17:485–493
  14. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma. Cancer. 2001;92:1759–1768
  15. O'Shaughnessy J. Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer. 2002;38(Suppl. 2):10–14
  16. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993;7:1245–1252
  17. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, et al. Vinorelbine as first line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994;12:336–341
  18. García-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, et al. Phase II trial of weekly i.v. vinorelbine as first line chemotherapy for metastatic breast carcinoma. Ann Oncol. 1994;5:854–857
  19. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol. 1994;12:2094–2101
  20. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, et al. Vinorelbine as salvage treatment for advanced breast cancer. Ann Oncol. 1994;5:423–426
  21. Trillet-Lenoir V, Sommer H, Delozier T, Koralewski P, Ruiz Simon A, et al. Oral vinorelbine in metastatic breast cancer: long-term results of 2 phase II studies. Eur J Cancer. 2004;2:137;(abstr 279)
  22. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003;2:135–140
  23. Gridelli C, Parlier Y, Brandely M, Aubert D, Nguyen L, Jassem , et al. Oral chemotherapy and upper gastro-intestinal tolerance improvement of nausea and vomiting in non-small cell lung cancer patients treated with oral navelbine and standard antiemetic prophylaxis. Eur J Cancer. 2003;1:S240;(abstr 801)
  24. Lorusso V, Crucitta E, Silvestris N, Guida M, Misino A, Latorre A, et al. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer. Clin Breast Cancer. 2003;4:138–141
  25. Nolè F, Catania C, Munzone E, Rocca A, Verri E, Sanna G, et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol. 2006;17:322–329
  26. Kellokumpu-Lehtinen PL, Sunela K, Lehtinen I, Joensuu H, Sjöström-Mattson J. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer. 2006;7:401–425
  27. Favier L, Isambert N, Zanetta S, Ferrant E, Mayer F, Chauffert B, et al. Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer. Breast. 2008;17:36–41
  28. Hess D, Thürlimann B, Pagani O, Aebi S, Rauch D, Ballabeni P, et al. Capecitabine and vinorelbine in elderly patients (> or = 65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol. 2004;15:1760–1766
  29. Estévez LG, Batista N, Sánchez-Rovira P, Velasco A, Provencio M, León A, et al. A phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer. 2008;8:149–154
  30. Nolè F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, et al. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2009;64:673–680
  31. Schott AF, Rae JM, Griffith KA, Hayes DF, Sterns V, Baker LH, et al. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol. 2006;58:129–135
  32. Lorusso V, Spada M, Giampaglia M, Misino A, Calabrese R, Latorre A, et al. Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer. A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol. 2006;17(Suppl. 7):vii15–vii17
  33. Hess D, Koberle D, Thurlimann B, Pagani O, Schonenberger A, Mattmann S, et al. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or = 65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology. 2007;73:228–237
  34. Miller AB, Hoogstraten BB, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  35. Simon R. Optimal two stage design for phase II clinical trials. Control Clinical Trials. 1989;10:1–10
  36. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with concurrent granulocyte colony stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997;15:1395–1400
  37. Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, et al. Efficacy and tolerance of vinorelbine and fluorouracil combination as first line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol. 1996;14:3097–3104
  38. Zambetti M, Demicheli R, De Candis D, Antonelli G, Giacobone A, Terenziani M, et al. Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. Breast Cancer Res Treat. 1997;44:255–265
  39. Froudarakis ME, Catimel G, Guastalla JP, Rebattu P, Clavel M. Phase II trial of navelbine and fluorouracil as second line chemotherapy in metastatic breast carcinoma. Oncology. 1998;5:87–88
  40. Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second or third line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol. 2000;8:3370–3377
  41. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812–2823
  42. Chan A, Verril M. Capecitabine and vinorelbine in metastatic breast cancer. Eur J Cancer. 2009;45:2253–2265
  43. Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, et al. Phase I/II study of capecitabine and vinorelbine pretreated patients with metastatic breast cancer. Ann Oncol. 2005;16:64–69
  44. Stuart N, Bishop JL, Johnson SRD, Smith IE, O'Brien M, Whipp EC, et al. Vinorelbine and capecitabine (VX) for advanced breast cancer a phase II study showing good activity and potential for further development. Proc Am Soc Clin Oncol. 2003;22:(abstr 183)
  45. Ahn JH, Kim SB, Kim TW. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci. 2004;19:547–553
  46. Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J. Phase II trial of capecitabine and vinorelbine as first line chemotherapy for metastatic breast cancer patients. Anticancer Res. 2006;26:2451–2456
  47. Gil-Delgado M, Boostan H, Garcia-Giralt E, Auclair G, Biville F, Khayat D. Oral vinorelbine in combination with capecitabine in advanced breast cancer. Proc Am Soc Clin Oncol. 2006;24(18S):10586
  48. Finek J, Holubec L, Svoboda T, Sefrhansova L, Pavlikova I, Votavova M, et al. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res. 2009;29:667–670
  49. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, et al. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international phase II trial. Br J Cancer. 2009;101:232–237

PII: S0960-9776(10)00017-2

doi: 10.1016/j.breast.2010.01.015

The Breast
Volume 19, Issue 3 , Pages 214-218 , June 2010

Article Tools